First results extremely positive
In a controlled
(double-blind) clinical study conducted at the University of British
Columbia, treatment with Current Technology's proprietary ETG device was
Generate regrowth or stop excessive hair loss in the majority
(96%) of the treatment group participants enrolled in
On average, treatment group participants experienced a
66% increase in hair count after 36 weeks of ETG
The study data were published in the International
Journal of Dermatology (July-August 1990) , a peer-reviewed
trial supported ETG's effectiveness
This trial was extended
for an additional 34 weeks. Members of the control group who had received
simulated or placebo treatment in the double-blind study were offered ETG
under medical supervision.
- Through the 70th week of treatment, participants experienced
continued significant and enhanced hair growth.
- Those who had
previously received the simulated treatments experienced regrowth of hair
after receiving ETG Treatments in the extended trial.
- No adverse
effects attributable to ETG were reported by any of the subjects or
observed by researchers participating in the study.
The data from the extended study were published in the International
Journal of Dermatology (December 1992) .
studies were conducted under the supervision of Dr. Stuart Maddin, then a
Clinical Professor of Dermatology at the University of British Columbia.
Multi-center trials confirm clinical benefits of ETG
A multi-center, controlled, 33-week clinical trial
was completed at eight centers across the United States and Canada.
Conducted under the supervision of Dr. Richard DeVillez, then Chief,
Division of Dermatology, University of Texas Health Sciences Center, the
results of this trial confirm that ETG provides a safe and effective
clinical benefit to men experiencing androgenetic alopeica. Reports are in
preparation for submission to the peer-reviewed literature. A total of 205
men completed the 33-week trial.
More recently, a pilot study was conducted in New Zealand on
a group of 14 women undergoing chemotherapy treatment for breast cancer.
The results are positive and have been published in a peer-reviewed
medical journal – Psycho-Oncology, Volume
11: 244 – 248 (2002) .